AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

AbbVie surged 17% since June 18 to a record $253.35, adding $65 billion in market value—six times its $10.9 billion Apogee buyout—driven by investor demand for long-term immunology growth despite near-term EPS dilution, as Skyrizi won expanded FDA approval and Humira sales fell.